Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator

Clinical and Experimental Metastasis

Volumn 17, Issue 5, 1999, Pages 431-436

  Yoshizaki, Tomokazu ^a   Sato, Hiroshi ^a   Murono, Shigeyuki ^c   Pagano, Joseph S ^b   Furukawa, Mitsuru ^c  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NONE

Author keywords

BZLF1; EBV; Metastasis; MMP; Nasopharyngeal carcinoma

Indexed keywords

GELATINASE B;

ANTIBODY TITER; ARTICLE; CANCER INVASION; DIMERIZATION; ENZYME INDUCTION; EPSTEIN BARR VIRUS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; NASOPHARYNX CARCINOMA; PROTEIN DOMAIN; TRANSACTIVATION;

DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; TRANS-ACTIVATORS; VIRAL PROTEINS;

EID: 0033391997     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006699003525     Document Type: Article

References (33)

1. 1. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extra-cellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191-17.
2. 2. Liotta L, Steeg P, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
3. 3. Bernhald E, Gruber S, Muschel R. Direct evidence linking expression of matrix metalloproteinase 9 (92 kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 1994; 91: 4293-7.
4. 4. Nakajima M, Welch D, Wynn D et al. Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 1993; 53: 5802-7.
5. 5. Klein G. Epstein-Barr virus strategy in normal and malignant neoplastic B cells. Cell 1994; 77: 791-3.
6. 6. Henle W, Henle G, Zajac BA et al. Differential reactivity of human serum with early antigens induced by Epstein-Barr virus. Science 1970; 169: 188-90.
7. 7. zur Hausen H, Schulte-Holthausen I, Klein G et al. EBV-DNA in biopsies of Burkitt's tumors and anaplastic carcinomas of the nasopharynx. Nature 1970; 228: 1056-8.
8. 8. Weiss LM, Movahed LA, Warnke RA et al. Detection of Epstein-Barr virus viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989; 320: 502-6.
9. 9. Pallesen G, Hamilton-Dutoit SJ, Rowe M et al. Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells. J Pathol 1991; 165: 289-9.
10. 10. Takada K, Shimizu N, Sakuma S et al. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol 1986; 57: 1016-22.
11. 11. Countrymann J, Miller G. Activation of expression of latent Epstein-Barr herpes virus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci USA 1985; 82: 4085-9.
12. 12. Zalani S, Holley-Guthrie E, Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci USA 1996; 93: 9194-9.
13. 13. Ragoczy T, Heston L, Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 1998; 72: 7978-84.
14. 14. Raab-Traub N, Flynn K. The structure of the ternimi of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47: 883-9.
15. 15. Lynn TC, Tu SM, Kawamura A. Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma. J Laryngol Otol 1985; 99: 567-72.
16. 16. Sixbey JW, Yao QY. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 1992; 255: 1578-80.
17. 17. Yip TC, Ngan KC, Lau WH et al. Possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLFI transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 1994; 74: 2414-24.
18. 18. Yoshizaki T, Sato H, Maruyama Y et al. Increased expression of membrane type I-matrix metalloproteinase in head and neck carcinoma. Cancer 1997; 79: 139-44.
19. 19. Sato H, Takeshita H, Furukawa M et al. Epstein-Barr virus BZLFI transactivator is a negative regulator of Jun. J Virol 1992; 66: 4732-6.
20. 20. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993; 8: 395-405.
21. 21. Yoshizaki T, Sato H, Furukawa M et al. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 1998; 95: 3621-6.
22. 22. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989; 86: 2336-40.
23. 23. Packham G, Economou A, Rooney CM, et al. Structure and function of the Epstein-Barr virus BZLFI protein. J Virol 1986; 64: 2110-6.
24. 24. Joab I, Nicolas J, Schwaab G et al. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer 1991; 48: 647-9.
25. 25. Cochet C, Martel-Renoir D, Grunewald V et al. Expression of the Epstein-Barr virus immediate early gene, BZLFI, in nasopharyngeal carcinoma tumor cells. Virology 1993; 197: 358-65.
26. 26. Mathew A, Cheng HM, Sam CK et al. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. Cancer Immunol Immunother 1994; 38: 68-70.
27. 27. de-Vathaire F, Sancho-Garnier H, de-The H et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow-up study. Int J Cancer 1988; 42: 176-81.
28. 28. Farrell PJ, Rowe D, Rooney C et al. Epstein-Barr virus BZLFI transactivator specifically binds to consensus ApI site and is related to c-fos. EMBO J 1989; 8: 127-32.
29. 29. Niedobitek G, Agathanggelou A, Nicholls JM. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: Viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. seminars in Cancer Biology 1996; 7: 165-74.
30. 30. Gutierrez MI, Bhatia K, Magrath I. Replicative viral DNA in Epstein-Barr virus associated Burkitt's lymphoma biopsies. Leukemia Res 1993; 17: 285-9.
31. 31. Pallesen G, Sandvej K, Hamilton-Dutoit SJ et al. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 1991; 78: 1162-5.
32. 32. Martel-Renoir D, Grunewald V, Touitou R et al. Qualitative analysis of Epstein-Barr virus lytic genes in nasopharyngcal carcinoma biopsies. J Gen Virol 1995; 76: 1401-8.
33. 33. TNM classification of malignant tumours. 4th ed. In Hermanek P, Sobin LH (eds). Berlin: Springer-Verlag, 1987.